###begin article-title 0
Overexpression of nuclear transport factor 2 may protect against diabetic retinopathy
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 13 18 <span type="species:ncbi:9606">human</span>
We performed human, animal, and in vitro studies to examine the potential role of nuclear transport factor 2 (NTF2) in conferring resistance to diabetic retinopathy (DR).
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 228 232 <span type="species:ncbi:10116">rats</span>
###xml 309 331 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 388 392 <span type="species:ncbi:10116">rats</span>
###xml 423 426 <span type="species:ncbi:10116">Rat</span>
Blood NTF2 levels were assessed in two groups of patients with type 2 diabetes mellitus. Group P patients had a history of proliferative DR (PDR), while group N patients did not. The retinal vasculature was examined in diabetic rats three months after they received an intravitreal injection of a recombinant adeno-associated virus (rAAV) vector overexpressing NTF2 (rAAV2-NTF2). Control rats were treated with rAAV2 only. Rat retinal capillary endothelial cells (RRCECs) were infected with rAAV2-NTF2, or with a vector expressing siRNA targeted against NTF2, to assess the effects of overexpression and inhibition of NTF2 on vascular endothelial growth factor (VEGF) expression (mRNA and protein).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 229 233 <span type="species:ncbi:10116">rats</span>
###xml 327 331 <span type="species:ncbi:10116">rats</span>
There was a strong trend for patients with DR to have lower blood NTF2 levels compared to those who did not have DR (0.10+/-0.01 versus 0.20+/-0.08, p=0.079). There was significantly less retinal blood vessel leakage in diabetic rats infected with rAAV2-NTF2 compared to controls (16.5+/-2.9 versus 24.7+/-7.3, p=0.039). These rats exhibited normal retinal vasculature and blood-retinal barrier function. VEGF expression was inhibited by NTF2 overexpression and stimulated by NTF2 inhibition, (protein [0.41+/-0.05 versus 0.23+/-0.06] and mRNA [0.37+/-0.04 versus 0.23+/-0.06] p<0.01 for all).
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 177 185 <span type="species:ncbi:9606">patients</span>
These finding suggest that NTF2 is a potential mediator of retinal vasculature integrity. NTF2 may act by altering VEGF expression, thereby influencing the development of DR in patients with diabetes mellitus.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 711 712 711 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 981 982 981 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 983 984 983 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 464 472 <span type="species:ncbi:9606">patients</span>
###xml 721 727 <span type="species:ncbi:8164">Suzuki</span>
Diabetic retinopathy (DR) and consequent vision loss or impairment is a common complication of type 2 diabetes mellitus (DM). To date, no effective therapy exists to treat this associated vision loss. Lack of glucose control and the chronic nature of the disease are key risk factors, but DR also contains a hereditary component. The aldose reductase (ALR2) gene (allele z-4) has been linked to the occurrence of DR [1]. Wang and colleagues [2] found that Chinese patients with type 2 DM exhibited phenotypic differences in terms of risk factors for DR, and that ALR2 was associated with microvascular complications. A study of Mexican Americans with DM revealed that retinopathy was linked to two chromosomes [3], while Suzuki et al. [4] reported that apolipoprotein was associated with the occurrence of DR. Other studies indicate that vascular endothelial growth factor (VEGF), genetic polymorphisms, and mitochondrial rRNA genetic polymorphisms may contribute to DR pathology [5,6].
###end p 11
###begin p 12
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
The onset of DR among DM patients is variable. Some patients acquire DR as soon as they develop DM, while others either do not exhibit symptoms, or have very mild symptoms even many years after the onset of DM [7]. An epidemiologic study of American patients with a 20-year history of DM revealed that 80% had developed DR [8]. Evidently there is a distinct cohort of individuals with DM who are somehow "immune" to the onset of DR. These findings suggest the existence of a genetic polymorphism that protects retinal blood vessels from the damage associated with DM. Given this and the knowledge that no current medication can effectively control the occurrence and development of DR, it would seem pertinent to search for and try to identify genes that may be involved in conferring resistance to DR.
###end p 12
###begin p 13
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 758 768 758 768 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 1003 1005 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 109 114 <span type="species:ncbi:9606">human</span>
###xml 758 768 <span type="species:ncbi:7227">Drosophila</span>
Nuclear transport factor 2 (NTF2) is a small guanosine 5'-diphosphate (GDP) Ran binding protein found in all human cell types. It is involved in regulating multiple processes, including cell cycle, immunoreactions, and apoptosis [9-11]. The main function of NTF2 is to facilitate transport of certain proteins into the nucleus via interaction with nucleoporin FxFG [12,13]. NTF2 also works as a GDP-dissociation inhibitor to mediate the GDP-Ran gradient, which is also involved nucleocytoplasmic transport [14-16]. The importance of NTF2 is illustrated by the findings that deletion of this gene results in lethality [17]. With regards to the eye, it has been reported that partial deletion or mutation of the NTF2 gene may cause heteroplasia in the eyes of Drosophila [17]. It has been further suggested that partial loss of NTF2 function might alter the nuclear import of Ran proteins during the immune response and that the loss of functional alleles may be associated with the strong eye phenotype [18].
###end p 13
###begin p 14
###xml 357 364 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 112 120 <span type="species:ncbi:9606">patients</span>
###xml 281 288 <span type="species:ncbi:9606">patient</span>
In this study,we obtained blood samples from patients who suffered DM, but not proliferative DR (PDR), and from patients who suffered DM and PDR. RNA was extracted from these samples and subjected to microarray analysis to search for genes differentially expressed between the two patient groups and hence perhaps associated with DR. One of these was NTF2 (Table 1).
###end p 14
###begin title 15
Summary of significant differential gene expression as determined by microarray analysis.
###end title 15
###begin p 16
###xml 189 197 <span type="species:ncbi:9606">patients</span>
###xml 275 279 <span type="species:ncbi:10116">rats</span>
###xml 307 310 <span type="species:ncbi:10116">rat</span>
The aim of the current study was to determine if NTF2 plays a role in conferring resistance to DR. A series of studies were performed. NTF2 gene expression was determined in a cohort of DM patients divided into those with PDR and those without. In vivo studies with diabetic rats and in vitro studies using rat retinal capillary endothelial cells (RRCECs)were performed to assess the effects of overexpression and inhibition of NTF2 expression on retinal vasculature and inhibition of retinal damage.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human study
###end title 18
###begin p 19
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
###xml 556 564 <span type="species:ncbi:9606">patients</span>
###xml 598 606 <span type="species:ncbi:9606">patients</span>
###xml 832 840 <span type="species:ncbi:9606">Patients</span>
###xml 1100 1108 <span type="species:ncbi:9606">patients</span>
###xml 1228 1236 <span type="species:ncbi:9606">patients</span>
###xml 1339 1347 <span type="species:ncbi:9606">patients</span>
###xml 1444 1452 <span type="species:ncbi:9606">patients</span>
Patients were classified into two groups: those without PDR (group N) and those with PDR (group P). Group N patients had a 20 to 25 year history of DM without PDR as confirmed by retinal photography and fluorescein angiography. Group P patients had a 20 to 25 year history of type 2 DM with active PDR in both eyes as confirmed by retinal photography. 59 patients in both groups were of similar age (average age 67.3 years old), weight, ethnicity (Han Chinese), equal gender distribution and resided in or around Guangzhou City, China. Living standards of patients in both groups were similar. All patients had been on insulin therapy for approximately two years. Glucose levels before and after meals were strictly controlled in Group N but not in Group P. The diagnosis of PDR was made in accordance with international standards. Patients with malignant tumors, other hereditary diseases, severe infectious diseases (i.e., tuberculosis, hepatitis B) by biochemical examination and asked about the disease history, and hypertension or unstable critical condition were excluded. A total of 22 and 37 patients met the inclusion criteria for groups N and P over a period of 14 months. Blood samples (2.5 ml) were obtained from 20 patients (we selected) in each group for microarray analysis. Thereafter, six blood samples from each group of patients were selected, along with samples from a cohort of healthy volunteers controls (the NO group, 6 patients were recruited, they live in Guangzhou China, and average age of 68.5 years, the blood samples was frozen in -20 degreesC), for evaluation of NTF2 gene expression.
###end p 19
###begin p 20
###xml 112 119 <span type="species:ncbi:9606">patient</span>
This research was approved by the ethics committee of Zhongshan Ophthalmic Center, Sun Yet-Sun University. Each patient signed a consent statement before entering the study.
###end p 20
###begin title 21
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
Quantitative real time PCR evaluation of NTF2 gene expression
###end title 21
###begin p 22
###xml 571 578 571 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 28 35 <span type="species:ncbi:9606">patient</span>
Total RNA was isolated from patient blood samples using Trizol reagent (Gibco, Los Angeles, CA) and purified by Qiagen RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). Synthesis of cDNA was performed using a Super-Script II cDNA synthesis Kit (Invitrogen Inc., Carlsbad, CA). Real-time PCR (RT-PCR) was performed using a Hotstar Taq polymerase kit (Qiagen) with SYBR Green technology (Applied Biosystems Inc., Foster City, CA) according to the manufacturer's instructions. Relative gene expression was determined. The primers used to detect 384 bp NTF2 are described in Table 2.
###end p 22
###begin title 23
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
Quantitative real time PCR evaluation of NTF2 gene expression.
###end title 23
###begin title 24
Construction and packaging of rAAV2-NTF-2
###end title 24
###begin p 25
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 294 301 294 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t3">Table 3</xref>
###xml 71 74 <span type="species:ncbi:10116">rat</span>
The coding sequence for NTF2 was obtained from the Sprague-Dawley (SD) rat cDNA bank and was extended using Golden Taq (Tiangen Biotech, Beijing, China). The method for construction and packaging rAAV2-NTF-2 has been described previously [19]: The oligonucleotide upper primer are described in Table 3, polymerase chain reaction (PCR) amplification was performed in a final volume of 50 mul. The following temperature conditions were used for the reactions: 3 min initial denaturation at 94 degreesC, then 32 cycles for 30 s denaturation at 94 degreesC; 30 s annealing at 56 degreesC, synthesis for 1 min at 72 degreesC. The amplified product was subcloned directly into vector pGEM-T. Gene sequence was verified by dideoxynucleotide sequencing. Digestion of the recombinant plasmid pGEM-T-NTF2 with EcoRI acquired the cDNA of NTF2 extracellular domain which was subcloned into the EcoRI site of the gene therapy vector pSNAV-2. Recombinant plasmid was examined by restriction enzyme digestion and named pSNAV- 2/NTF2.
###end p 25
###begin title 26
###xml 34 38 34 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 30 33 <span type="species:ncbi:10116">rat</span>
Cloning and sequencing of the rat NTF2 gene.
###end title 26
###begin p 27
###xml 395 396 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">8</sup>
###xml 295 299 <span type="species:ncbi:10298?0.9473684210526315">HSV1</span>
Transfection of baby hamster kidney (BHK-21) cells with cells with pSNAV-NTF-2 was performed in six-well plates using a Lipofectamine 2000 kit (Invitrogen). These cells, named BHK/NTF-2, were then transferred and cultured in a 110 mmx480 mm flask (Wheaton Inc., Wheaton, IL), then infected with HSV1-rc/DeltaUL2 (Benyuan Zhengyang Inc., Beijing, China; MOI=0.1) when the cell number reached 8x108. The cells were then divided into 250 ml Fernbach culture flasks for further purification after 48 h culture.
###end p 27
###begin p 28
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 255 257 255 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sup>
The rAAV2-NTF-2 virus was purified and identified using RT-PCR as described previously [19]. The titer of rAAV2-NTF-2 (virus genome/ml [vg/ml]) was detected using in situ hybridization with a digoxin-labeled cytomegalovirus probe. The final titer was 1x1012 virus genomes/ml.
###end p 28
###begin title 29
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 54 57 <span type="species:ncbi:10116">rat</span>
In vivo study: overexpression of the NTF2 gene in the rat retina
###end title 29
###begin p 30
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 124 128 <span type="species:ncbi:10116">rats</span>
###xml 162 166 <span type="species:ncbi:10116">Rats</span>
###xml 243 247 <span type="species:ncbi:10116">Rats</span>
###xml 314 318 <span type="species:ncbi:10116">rats</span>
###xml 335 338 <span type="species:ncbi:10116">rat</span>
###xml 463 467 <span type="species:ncbi:10116">Rats</span>
###xml 615 619 <span type="species:ncbi:10116">rats</span>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
Obtained from the animal center of Huazhong University of Science and Technology were 60, two-month-old male Sprague Dawley rats, weighing between 150 and 200 g. Rats maintained in an cleaning environment for two weeks before experimentation. Rats were randomly divided into two groups, A and B, and containing 30 rats per group. Each rat in Group A received an intravitreal injection of purified rAAV2-NTF2 in either the left or right eye (determined randomly). Rats in Group B were injected with rAAV2 only. Diabetes animal model were Constructed after rAAV2 treatment one month: after fasting for 12 h [20], the rats were injected with a single dose of streptozotocin (STZ; 65 mg/kg intraperitoneal injection in 0.01 M citrate buffer with a pH of 4.5). Nondiabetic control mice received citrate buffer only. Fasting plasma glucose was examined after 3 days of STZ injection, and diabetes was confirmed by fasting plasma glucose value of 16.7 mmol/l or higher using Touchtrade mark Glucometer (Boehringer Mannheim Diagnostics, Indianapolis, IN). Retinal integrity was assessed two months later.
###end p 30
###begin title 31
Assessment of retinal blood vessel leakage
###end title 31
###begin p 32
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 160 164 <span type="species:ncbi:10116">Rats</span>
###xml 869 872 <span type="species:ncbi:10116">rat</span>
Retinal vascular permeability was determined by assessing fluorescein isothiocyannate-dextran (FITC- dextran) [21-23] and Evans Blue (EB) retinal leakage [24]. Rats were anesthetized by intraperitoneal injection of 50 mg/kg ketamine and 20 mg/kg chlorpromazine. Next, a 100 mg/kg solution of FITC-dextran solution (Sigma, St Louis, MO) or 45 mg/kg of 3% EB (Sigma) was injected via the tail vein. The chest was opened after 2 h and an infusion tube connected with a 14G blunt needle was inserted into the left ventricle. The right atrial appendage was cut open, and the heart was infused with fluid contained 0.05 M 1% paraformaldehyde citrate buffer, pH 3.5, at 250 ml/kg bodyweight. Infusion height was 160 cm, resulting in an equivalent infusion pressure of 120 mmHg. The infusion was maintained for 2 min to remove any remnant dye in the blood vessels. The eyes of rat were then removed, and the retina was dissected and mounted to determine retinal blood vessel leakage (FITC-dextran leakage) by microscopy.
###end p 32
###begin p 33
###xml 172 176 <span type="species:ncbi:10116">rats</span>
To assess EB leakage, we dried dissected retinas under vacuum (45 degreesC for 5 h). The retinal dry weight was recorded. The difference in retinal weight between diabetic rats injected with rAAV2-NTF2 and controls was compared. Next, 120 mul formamide was added and the solution placed in a 70 degreesC water bath for 18 h. The sample was then centrifuged at 7,280 xg for 30 min to separate the dye from the protein. The absorbance of the 50 mul filtered fluid was detected at wavelengths of 620 nm and 740 nm using a Beckman DU-640 spectrophotometer (Beckman Coulter, Fullerton, CA). The net absorbance was calculated by subtracting the absorbance at 740 nm from that at 620 nm. The concentration of dye was calculated from a standard curve (determined for each measurement) of EB in formamide. Samples were analyzed in triplicate and the mean calculated. The dry weight of the retina (mg) was used to standardize dye content and values are presented in ng/mg. The formula was as follows:
###end p 33
###begin p 34
EB content in the retina (ng/mg)=[EB concentration in formamide (ng/mul)x120 (mul)]/dry weight of the retina (mg)
###end p 34
###begin title 35
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
In vitro studies: inhibition of NTF2 expression using siRNA
###end title 35
###begin p 36
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 800 801 788 789 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1063 1064 1051 1052 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 1141 1142 1129 1130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 78 81 <span type="species:ncbi:10116">rat</span>
###xml 495 500 <span type="species:ncbi:9606">human</span>
###xml 609 615 <span type="species:ncbi:9913">bovine</span>
###xml 996 1001 <span type="species:ncbi:9606">human</span>
In vitro cultured RRCECs were prepared as previously described [25]. Briefly, rat eyes were cut circumferentially 1.5 mm posterior to the limbus, and the retinas were harvested and homogenized by two gentle up-and-down strokes in a 15 ml homogenizer (Dounce; Bellco Glass Co., Vineland, NJ). The homogenate was filtered. The remaining retentate was digested in 0.066% collagenase for 45 min at 37 degreesC. The homogenate was centrifuged (1,000x g for 10 min), and the pellet was resuspended in human serum-free endothelial-basal growth medium Invitrogen-Gibco, Grand Island, NY), supplemented with 20% fetal bovine serum, 50 U/ml endothelial cell growth factor (Sigma-Aldrich). Cells were cultured in fibronectin-coated dishes and incubated at 37 degreesC in a humidified atmosphere containing 5% CO2. Cultured RRCECs were transfected with rAAV2-NTF2, or rAAV2-GFP. Cells were plated in 24 well culture plates, grown overnight to 70%-80% confluence. Cells were then washed twice with serum-free human endothelial-serum-free medium basal growth medium. Next, 1x109 vg/ml rAAV2-NTF2 was added to each well in the experimental group while 1x109 vg/ml rAAV2 only was added to control wells. rAAV2-GFP was added to six separate wells to monitor infection efficiency (subsequently found to approximate 93%).
###end p 36
###begin p 37
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 291 298 291 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t4">Table 4</xref>
###xml 490 494 490 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 499 503 499 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
A vector containing siRNA for NTF2 was constructed by cloning the double stranded sequence into the RNAi-Ready pSIREN-RetroQ ZsGreen vector (pSIREN vector; BD Biosciences, Franklin Lakes, NJ) to yield the pSIREN-NTF2 siRNA vector. The NTF2 sequences (obtained from Qiagen) were described in Table 4. RRCECs were infected with pSIREN-NTF2 siRNA or pSIREN vectors using Lipofectamine. Real time PCR and western blot analyses were performed to examine the RNA and protein expression levels of NTF2 and VEGF two days after infection.
###end p 37
###begin title 38
###xml 9 13 9 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
The RNAi NTF2 sequence.
###end title 38
###begin title 39
Quantitative real time PCR and western blot evaluation of NTF2 and VEGF gene and protein expression
###end title 39
###begin p 40
###xml 507 514 507 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t5">Table 5</xref>
###xml 902 906 <span type="species:ncbi:9925">goat</span>
###xml 1165 1170 <span type="species:ncbi:10090">mouse</span>
###xml 1176 1181 <span type="species:ncbi:9606">human</span>
Total RNA was isolated from RRCECs using Trizol reagent (Gibco, Los Angeles, CA) and purified by Qiagen RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). Synthesis of cDNA was performed using a Super-Script II cDNA synthesis Kit (Invitrogen Inc.). Real-time PCR was performed using a Hotstar Taq polymerase kit (Qiagen) with SYBR Green technology (Applied Biosystems Inc., Foster City, CA) according to the manufacturer's instructions. Relative gene expression was determined. The primers were described in Table 5. Total protein was extracted from RRCECs using bicinchoninic acid. Isolated protein was mixed with loading buffer, denatured for 6 min at 60 degreesC, cooled, centrifuged for 5 min, and then separated by sodium-dodecyl sulfate PAGE (SDS-PAGE). Antibodies directed toward NTF2 and VEGF (Santa Cruz Biotechnology Inc., Santa Cruz, CA) were used to probe the proteins. A secondary antibody goat anti-mouseIgG-HRP (1:1,000 dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA) was applied, and the signal was revealed by chemiluminescence. The polyvinylidene fluoride membranes were reused to detect beta-actin (internal control) by incubating with a mouse anti-human actin antibody (Gene Co, Hong Kong, China). The bands detected were analyzed by automatic image analysis, and the integrated optical density (OPTDI) of each protein band was normalized to the OPTDI value of the corresponding beta-actin band from the same sample.
###end p 40
###begin title 41
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Quantitative real time PCR evaluation of NTF2 AND VEGF expression.
###end title 41
###begin title 42
Statistical analysis
###end title 42
###begin p 43
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Normally distributed data were compared by independent two samples t-test or one-way ANOVA where appropriate. When a significant difference was detected between groups differences were detected, multiple comparisons of means were performed using the Bonferroni procedure, with type-I error rate at a maximum of 0.017(0.05/3) adjustment. Statistical analyses were performed using SPSS 15.0 statistics software (SPSS Inc., Chicago, IL), and differences were considered significant when p<0.05. Data are presented as the mean+/-standard deviation (SD).
###end p 43
###begin title 44
Results
###end title 44
###begin title 45
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
NTF2 expression in patients
###end title 45
###begin p 46
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 256 264 252 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 267 271 263 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 429 433 421 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
There was a significant overall difference in NTF2 gene expression among the groups (NO, N, and P). NTF2 expression was lower in group N patients compared to NO (control), however this difference was insignificant (0.20+/-0.08 versus 0.26+/-0.09, p=0.479; Figure 1). NTF2 expression was significantly higher in normal compared to group P patients (0.26+/-0.09 versus 0.10+/-0.01; p=0.004). There was no significant difference in NTF2 expression between group N and P patients.
###end p 46
###begin p 47
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
NTF2 expression was significantly lower in patients with PDR. Expression of NTF2 mRNA as determined by real-time PCR in patients with type 2 diabetes mellitus (DM) and proliferative diabetic retinopathy (PDR, group P), DM without PDR (group N) and healthy volunteers (group NO). Asterisk indicates significance between groups difference (p<0.05).
###end p 47
###begin title 48
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 65 69 <span type="species:ncbi:10116">rats</span>
Effect of NTF2 overexpression on retinal blood vessel leakage in rats with DM
###end title 48
###begin p 49
###xml 252 260 248 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 74 78 <span type="species:ncbi:10116">rats</span>
###xml 126 130 <span type="species:ncbi:10116">rats</span>
The FITC-dextran blood vessel leakage area was significantly decreased in rats treated with rAAV2-NTF2 compared to in control rats (11.3+/-1.5% versus 23.7+/-2.8%; p<0.05). Representative images demonstrating retinal leakage of FITC dye can be seen in Figure 2.
###end p 49
###begin p 50
###xml 137 138 137 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 143 145 143 145 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B.</bold>
###xml 212 213 212 213 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 218 220 218 220 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D.</bold>
###xml 338 339 337 338 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 344 345 343 344 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 359 360 357 358 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 365 366 363 364 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 31 35 <span type="species:ncbi:10116">rats</span>
###xml 119 123 <span type="species:ncbi:10116">rats</span>
###xml 193 197 <span type="species:ncbi:10116">rats</span>
###xml 289 293 <span type="species:ncbi:10116">rats</span>
Retinal sections from diabetic rats infused with fluorescein isothiocyanate. Representative images from rAAV2-infected rats was shown on A and B. Representative images from rAAV2-NTF2-infected rats were shown on C and D. Decreased blood vessel leakage was apparent in retinas from group B rats (NTF2 overexpression). Scale bar=50 mum for A and C, 100 mum for B and D.
###end p 50
###begin p 51
###xml 99 103 <span type="species:ncbi:10116">rats</span>
There was significantly less EB content in retinas from rAAV2-NTF2 injected as compared to control rats (16.5+/-2.9 ng/mg retinal dry weight versus 24.7+/-7.3 ng/mg retinal dry weight; p=0.039).
###end p 51
###begin title 52
###xml 11 15 11 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Effects of NTF2 overexpression and downregulation on VEGF expression in RRCECs
###end title 52
###begin p 53
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 169 173 165 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 265 269 257 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 398 402 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 683 692 663 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3A</xref>
###xml 697 706 677 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4B</xref>
###xml 828 837 804 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3B</xref>
###xml 842 851 818 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4D</xref>
###xml 969 978 945 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3C</xref>
###xml 1015 1024 987 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4F</xref>
###xml 1126 1135 1098 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3D</xref>
###xml 1172 1181 1140 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4H</xref>
Real time PCR revealed that infection of RRCECs with rAAV2-NTF2 resulted in significant upregulation of NTF2 mRNA (0.77+/-0.05 versus 0.51+/-0.02, p<0.01), In contrast, VEGF mRNA were significantly decreased in these cells (0.19+/-0.03 versus 0.28+/-0.03, p<0.01). NTF2 mRNA were significantly decreased following transfection with pSIREN-NTF2 siRNA (0.27+/-0.06 versus 0.55+/-0.08; p<0.01). While VEGF mRNA were significantly increased in these compared to control cells (0.37+/-0.04 versus 0.23+/-0.06; p<0.01). Western blot analyses confirmed that Infection of RRCECs with rAAV2-NTF2 resulted in significant upregulation of NTF2 protein expression (1.03+/-0.20 versus 0.55+/-0.13,Figure 3A and Figure 4B; p<0.01). In contrast, VEGF protein levels (0.76+/-0.14 versus 1.26+/-0.17) were significantly decreased in these cells (Figure 3B and Figure 4D; p<0.01). NTF2 protein expression levels were significantly decreased following transfection with pSIREN-NTF2 siRNA (Figure 3C and 0.46+/-0.07 versus 1.01+/-0.10; Figure 4F; p<0.01). While VEGF protein levels were significantly increased in these compared to control cells (Figure 3D and 0.41+/-0.05 versus 0.23+/-0.06; Figure 4H; p<0.01)
###end p 53
###begin p 54
###xml 26 30 26 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 185 189 185 189 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A, B</bold>
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 309 313 309 313 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C, D</bold>
###xml 350 353 <span type="species:ncbi:10116">rat</span>
Effects of NTF2 levels on NTF2 and VEGF mRNA expression. Overexpression of NTF2 by transfection of rAAV2-NTF2 increased the expression level of NTF2 but reduced the expression of VEGF (A, B). Downregulation of NTF2 by transfection with pSIREN-NTF2 siRNA reduced NTF2 expression but increased VEGF expression (C, D). The experiments were performed in rat retinal capillary endothelial cells. Asterisk (*) indicates a significant difference between groups (p<0.05).
###end p 54
###begin p 55
###xml 181 185 181 185 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B, D</bold>
###xml 318 322 318 322 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F, H</bold>
###xml 507 511 507 511 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A, E</bold>
###xml 523 527 523 527 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C, G</bold>
###xml 359 362 <span type="species:ncbi:10116">rat</span>
Effects of NTF2 expression on NTF2 and VEGF protein levels. Overexpression of NTF2 by transfection with rAAV2-NTF2 increased NTF2 protein expression but reduced VEGF protein level (B, D). Downregulation of NTF2 by transfection with pSIREN-NTF2 siRNA inhibited NTF2 protein expression but increased VEGF protein level (F, H). The experiments were performed in rat retinal capillary endothelial cells. Representative western blots were shown for the effects of NTF2 overexpression and downregulation on NTF2 (A, E) and VEGF (C, G) preotein expression. Asterisk (*) indicates a significant difference between the groups (p<0.05).
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 156 160 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 492 496 492 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 284 290 <span type="species:ncbi:9606">humans</span>
###xml 375 379 <span type="species:ncbi:10116">rats</span>
###xml 748 754 <span type="species:ncbi:9606">humans</span>
The results of this study suggest that NTF2 may be involved in mediating DR in patients with DM. Several lines of evidence support this assertion. We found NTF2 mRNA expression to be lower in DM patients with PDR (P group) compared to those without PDR. Even though the difference in humans was not statistically significant, we also found overexpression of NTF2 in diabetic rats was associated with decreased indices of retinal damage. Findings from our in vitro studies of RRCECs, in which NTF2 expression was upregulated or downregulated, indicated that NTF2 modulates VEGF expression. This is an important observation given that NTF2 may play a role in mediating the progression of DR and suggests the need for further studies, particularly in humans.
###end p 57
###begin p 58
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
DR is among the most prevalent complications associated with DM. Hence, it is closely related to DM. Several studies have suggested that there is a genetic component to PDR [2,3,6,26]. It would appear that genes involved help maintain functionality of the retinal blood vessels and protects the surrounding tissue from DM-related damage.
###end p 58
###begin p 59
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
###xml 568 575 <span type="species:ncbi:9606">patient</span>
###xml 613 621 <span type="species:ncbi:9606">patients</span>
At the beginning of study, we examined NTF2 expression levels in patients, who had DM with or without PDR for 20-25 year. Potential confounding factors (e.g., age, gender, types of illness, and living conditions) were eliminated due to a strict selection and exclusion criteria of patients. Hence the differentiating factor between the 2 groups of patients was the presence or absence of PDR. We found that NTF2 levels in patients with PDR were significantly lower than in normal healthy individuals (NO) While there was no significant difference detected between the patient groups, there was a strong trend for patients with PDR to have lower NTF2 levels (p=0.079). This lack of a difference between these groups may be a reflection of the relatively small sample size. Nevertheless, this finding encouraged us to further examine the importance of NTF2 with regards to the development of DR.
###end p 59
###begin p 60
###xml 51 53 51 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 202 206 202 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 372 376 372 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 437 441 437 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NTF2</italic>
###xml 183 193 <span type="species:ncbi:7227">Drosophila</span>
###xml 326 336 <span type="species:ncbi:7227">Drosophila</span>
###xml 453 463 <span type="species:ncbi:7227">Drosophila</span>
Findings from a study by Minakhina and colleagues [17] have interesting parallels to our own. These researchers found that low NTF2 gene expression resulted in abnormal eye growth in Drosophila. Higher NTF2 gene expression was required to maintain normal eye growth. The number of compound eyes was significantly decreased in Drosophila with reduced as compared to normal NTF2 expression. The decreased frequency of compound eyes in low NTF2 expression Drosophila may have been due to dysplasia of blood vessels in the eye.
###end p 60
###begin p 61
###xml 17 21 17 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VEGF</italic>
Given that lower VEGF expression is thought to be associated with DR resistance [27], it is plausible that NTF2 may offer protection from DR by depressing VEGF expression. Indeed our findings suggest that this may be the case (at least in part). We found that expression of NTF2 in RRCECs was inversely related to VEGF expression (both mRNA and protein). Precisely how NTF2 might influence VEGF expression is unclear. Further studies examining the effects of NTF2 on downstream inflammatory and vascular factors are warranted to clarify this point. Certainly, NTF2 may influence other mediators of DR aside from VEGF.
###end p 61
###begin p 62
###xml 221 229 <span type="species:ncbi:9606">patients</span>
In summary, the findings from our study implicate NTF2 as a potential mediator of retinal vasculature protection and suggest that expression levels of this gene may dictate, at least to some extent, development of PDR in patients with DM. Our findings also suggest that NTF2 may exert such effects by altering VEGF expression. Further studies are warranted to examine potentials pathways through which NTF2 may be exerting such effects.
###end p 62
###begin title 63
Acknowledgments
###end title 63
###begin p 64
This work was supported by grants from the National Nature Science Foundation of China (grant numbers 30872823, 30471849, and 30672278). Dr. Bin Li (scotopsin@yahoo.com.cn) and Professor Shi-Bo Tang contributed equally to the work and can be considered co-corresponding authors.
###end p 64
###begin title 65
References
###end title 65
###begin article-title 66
Molecular genetics of microvascular disease in diabetic retinopathy.
###end article-title 66
###begin article-title 67
Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes.
###end article-title 67
###begin article-title 68
A genome-wide linkage scan for diabetic retinopathy susceptibility genes in Mexican Americans with type 2 diabetes from Starr County, Texas.
###end article-title 68
###begin article-title 69
Relation of apolipoprotein (a) phenotypes to diabetic retinopathy in elderly type 2 diabetes.
###end article-title 69
###begin article-title 70
A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes.
###end article-title 70
###begin article-title 71
A familial case of proliferative diabetic retinopathy associated with a mutation in the mitochondrial gene.
###end article-title 71
###begin article-title 72
###xml 134 142 <span type="species:ncbi:9606">patients</span>
HLA DRB1, DQB1, and insulin promoter VNTR polymorphisms: interactions and the association with adult-onset diabetes mellitus in Czech patients
###end article-title 72
###begin article-title 73
The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.
###end article-title 73
###begin article-title 74
Cell cycle regulated transport controlled by alterations in the nuclear pore complex.
###end article-title 74
###begin article-title 75
###xml 4 14 <span type="species:ncbi:7227">Drosophila</span>
The Drosophila homolog of NTF-2, the nuclear transport factor-2, is essential for immune response.
###end article-title 75
###begin article-title 76
Nucleocytoplasmic transport in apoptosis.
###end article-title 76
###begin article-title 77
Solution NMR study of the interaction between NTF2 and nucleoporin FxFG repeats.
###end article-title 77
###begin article-title 78
Association of nuclear pore FG-repeat domains to NTF2 import and export complexes.
###end article-title 78
###begin article-title 79
NTF2 mediates nuclear import of Ran.
###end article-title 79
###begin article-title 80
Nuclear transport factor p10/NTF2 functions as a Ran-GDP dissociation inhibitor (Ran-GDI).
###end article-title 80
###begin article-title 81
Significant proportions of nuclear transport proteins with reduced intracellular mobilities resolved by fluorescence correlation spectroscopy.
###end article-title 81
###begin article-title 82
Crosstalk between the actin cytoskeleton and Ran-mediated nuclear transport.
###end article-title 82
###begin article-title 83
Monoclonal antibodies to NTF2 inhibit nuclear protein import by preventing nuclear translocation of the GTPase Ran.
###end article-title 83
###begin article-title 84
Decrease in retinal progenitor cells is associated with early features of diabetic retinopathy in a model that combines diabetes and hypertension.
###end article-title 84
###begin article-title 85
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse.
###end article-title 85
###begin article-title 86
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
Structural and hemodynamic analysis of the mouse retinal microcirculation.
###end article-title 86
###begin article-title 87
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 116 123 <span type="species:ncbi:9986">rabbits</span>
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.
###end article-title 87
###begin article-title 88
###xml 129 133 <span type="species:ncbi:10116">rats</span>
Study of the influence of angiostatin intravitreal injection on vascular leakage in retina and iris of the experimental diabetic rats.
###end article-title 88
###begin article-title 89
Protective effects of transcription factor HESR1 on retinal vasculature.
###end article-title 89
###begin article-title 90
Genetics of diabetic retinopathy.
###end article-title 90
###begin article-title 91
Nuclear import of Ran is mediated by the transport factor NTF2.
###end article-title 91

